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Abstract
Introduction: Human herpesvirus 6 (HHV-6) has been recognized as a potentially significant pathogen in hemopoietic stem
cell transplant (HSCT) recipients. Different clinical manifestations have been described, including fever, skin rash, bone
marrow suppression, and encephalitis.
Materials and Methods: A retrospective review of a group of 26 adult recipients of allogeneic HSCTs was conducted. Serum
samples taken before transplant were examined for the presence of specific anti-HHV-6 IgM and IgG antibodies. After
transplantation, quantitative real-time PCR was used to determine viral load in plasma samples from days 0–180 post-trans-
plant.
Results: HHV-6 DNA was detected in plasma samples in 8 (30%) of the 26 recipients between days 18 and 40 after trans-
plantation. All of them developed fever of unknown origin and over 50% had graft-versus-host disease features. Three indi-
viduals from this group died during detectable HHV-6 viremia. Another two recipients showed a single positive PCR result
at a later time. Infection with HHV-6 was thus confirmed in 10 (38.5%) of the 26 graft recipients.
Conclusions: There is a high frequency of detectable HHV-6 viral load in stem cell transplant recipients in Poland. Further
investigation to monitor HHV-6 reactivation in graft recipients will be important to improve outcome for these patients.
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INTRODUCTION
Human herpesvirus type 6 (HHV-6) belongs to the
subfamily β-herpesvirinae and is closely related to HHV-7
and HHV-5 (formerly known as cytomegalovirus –
CMV) [5]. Most people have had a primary HHV-6
infection in early childhood [3] and the virus is wide-
spread in the human population, as shown by the pres-
ence of specific antibodies in 90% of healthy adults [17].
As a result of the primary infection, HHV-6 is assumed
to establish a latent infection and viral DNA can be
detected in salivary glands [7], monocytes [10], and early
bone marrow progenitor cells [13]. 
HHV-6 is reported to be a causative agent of exan-
thema subitum [20] and has been associated with
a broad spectrum of diseases, including febrile convul-
sions [11], encephalopathy [9, 18], hepatitis [6], and lym-
phoproliferative disorders [15]. An active HHV-6 infec-
tion can cause fatal disease in an immunocompromised
host, including patients after stem cell transplantations
(SCTs), but fatal outcome in immunocompetent per-
sons due to HHV-6 infection is extremely rare [14, 16].
HHV-6 presence in plasma or serum was document-
ed in 33–48% of hemopoietic stem cell transplant
(HSCT) recipients using molecular techniques [22]. The
peak viral load occurs early after transplantation andusually within the first four weeks after transplantation
[4, 21]. Allogeneic SCT, advanced hematological dis-
ease, young age, gender mismatch between the donor
and recipient, and treatment with corticosteroids are
commonly reported risk factors associated with HHV-6
infection after transplantation [4, 21].
In a recent study we summarized retrospective
results of the determination of HHV infection status in
allogeneic stem cell transplant recipients. As infections
with HHV-6 are rarely accompanied by clinical symp-
toms, our first aim was to compare HHV-6 infection sta-
tus, measured as viral DNA presence in the blood in the
post-transplantation period and patients’ anti-HHV-6
serological status by detection of IgG and IgM antibod-
ies. This allowed us to determine both the presence of
active infection and whether a recent infection was
a result of primary contact with the virus or the reacti-
vation of latent virus, which should be valuable informa-
tion in terms of comparing HHV-6 infection status and
clinical status of an infected patient.
Another virus belonging to the β-herpesvirinae sub-
family, HHV-5 (CMV), is one from the most important
viral pathogens causing clinical infections in patients
receiving immunosuppressive treatment. As there is
information in published data about a connection
between HHV-5 and HHV-6 reactivation in graft recip-
ients, our aim was to determine the appearance of
simultaneous reactivation of both β-herpesviruses. We
believe that this is probably the first report from Poland
involving this kind of examination in HSCT recipients.
MATERIALS AND METHODS
This retrospective study involved patients who
received an allogeneic HSCT and were hospitalized at the
Hematology, Oncology, and Internal Medicine Clinics,
Medical University of Warsaw. In the period under con-
sideration (December 2004 to October 2006) there were
38 patients receiving allogeneic stem cell transplants. The
criteria for patient selection for the study included the
appearance of at least one syndrome from those listed
below within a period of 100 days after HSCT: pneumo-
nia, appearance or intensification of graft-versus-host dis-
ease (GvHD), skin rash, or pyrexia of unknown origin.
Introduction of these criteria resulted in a group to 26
adult receivers of HSCTs (Table 1). Monitoring of clinical
status of the patients and viral load in blood samples com-
prised a period of 180 days after HSCT.
IgG and IgM antibodies against HHV-6 were mea-
sured from the panel of 26 serum specimens, collected
once before HSCT, from the patients with different
hematological disorders using a commercial enzyme
immunoassay (PanBio). The results obtained with both
HHV-6-specific IgG and IgM tests were expressed in
PanBio units (PBU). The PBU is calculated as the ratio
of the sample absorbance to the cut-off absorbance and
multiplied by 10 (absorbance of sample/mean
absorbance of cut-off ×10).
The collection of plasma samples from all patients
for HHV-5 PCR investigations, according EBMT guide-
lines, began at a median of 3 days after transplantation
(range: 1–7 days) and lasted until a median of 105 days
(range: 30–180 days).Routine collection of plasma sam-
ples was performed once a week until the 100th day
after allogeneic HSCT, thereafter once every two weeks,
up to 180th day after HSCT. The median number of
blood samples per patientwas 12 (range: 3–21). Atotal
of 294 samples from the 26 patientswere collected. For
the purpose of recent study, viral DNA was extracted
from 200 µl of each plasma sample using a QIAmp®
DNA Blood Mini Kit (Qiagen) in accordance with the
manufacturer’s instructions and retrospectively used for
detection of HHV-6 DNA.
For the detection of HHV-6, a real-time PCR assay
with fluorescent probes complementary to the sequence
lying within the amplified product was used. The tests
were run on a LightCycler 2.0 instrument (Roche) with
the commercial quantitative MutaREAL® HHV-6 kit
(ALPCO). All samples were examined according to the
manufacturer’s instructions. Every tested sample was
amplified with an internal control (positive control of
the DNA extraction and amplification process). Each
amplification reaction also included, besides the tested
samples, positive HHV-6-specific controls and a nega-
tive control of the DNA extraction and amplification
process.
HHV-5 DNA was detected using the commercial
real-time test CMV Quant Kit® (Roche) developed for
the LightCycler 2.0 instrument. The test uses internal
SCORPIONS™ fluorescent probes for the PCR ampli-
fication product. Analogously to HHV-6 detection, for
every sample an internal control was added and the
amplification was performed in the presence of amplifi-
cation-specific controls (positive, negative, and extrac-
tion process control).
RESULTS
Specific IgM antibodies were present in the serum of
2 (8%) patients, while the others were negative (92%).
Twenty of the 26 persons (77%) had IgG antibodies
against HHV-6 before HSCT and the other 6 (23%)
were negative. Of the group of 16 patients who had no
detectable HHV-6 during the entire post-transplanta-
tion period, 10 (62.5% of the HHV-6-negative patients)
had a positive result only for the anti-HHV-6 IgG test,
but no anti-HHV-6 IgM, in serum sample taken direct-
ly before transplantation, 4 (31.3%) were both IgM and
IgG negative, and the remaining patient had anti-HHV-6
antibodies of both classes (Table 1).
The serological status of the 10 patients who had
HHV-6 DNA detected in one or more blood samples
was very similar: 7 patients (70%) had only IgG, 2
patients (20%) had no IgG or IgM antibodies, and one
patient had HHV-6-specific IgG and IgM.
Regarding the amplification results of DNA isolated
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the presence of exponential increases in fluorescence,
products were detected in 29 samples (10%) taken from
10 patients (38%). Two of them (8%) had HHV-6 DNA
in only a single positive sample and another 8 (30%) had
positive results in two or more subsequent tests. In the
patients with two or more plasma samples containing
HHV-6 DNA, viremia was observed between days 18
and 40 after transplantation (Table 1). In the two
patients who had a single HHV-6-positive blood sample,
viral DNA was detected at a later time. The quantitative
results obtained by the MutaREAL® HHV-6 test in all
positive cases were at low levels, between 700–1600
copies/ml.
HHV-5 DNA was detected in the plasma samples
collected from four HHV-6-negative patients. In all four
cases, HHV-5 DNAemia was observed in the typical
period of 40–65 days after transplantation and, more-
over, a second HHV-5 viremia course occurred in two
patients starting at days 103 and 123 after transplanta-
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Table 1. Characteristics of patients investigated for human herpesvirus 6 after HSCT
Patient no. Sex Age Disease SCT
HHV-5 DNA HHV-6 DNA HHV-6 IgM HHV-6 IgG
in plasma in plasma before SCT before SCT
(days after SCT) (days after SCT)
1 female 20 CML uCBSCT ++ – – +
(43–65)
2 male 40 AML uPBSCT – ++ – +
(20–30)
3 female 41 AML uPBSCT – – – –
4 female 33 ALL rPBSCT – – – +
5 female 22 ALL uPBSCT ++ – – +
(64–72)
6 male 32 ALL uCBSCT – – – –
7 male 32 aplasia rPBSCT – ++ + +
(18–25)
8 male 18 AML uPBSCT ++ – – –
(61; 123–130)
9 male 19 AML uPBSCT – + – +
(63)
10 male 56 AML rPBSCT – ++ – +
(21–38)
11 male 28 AML uBMT ++ – + +
(58–75; 103–110)
12 male 51 AML uBMT – – – –
13 male 18 MDS rBMT – ++ – +
(18–34)
14 male 44 AML rPBSCT – ++ – +
(26–40)
15 male 43 AML rPBSCT – – – +
16 male 49 AML rPBSCT – – – +
17 female 20 ALL rPBSCT – – – +
18 male 27 ALL uCBSCT – – – +
19 male 49 MDS rPBSCT – ++ – –
(19–23)
20 female 24 ALL uPBSCT – – – +
21 female 19 AML uPBSCT – – – +
22 male 33 ALL uPBSCT – + – +
(58)
23 female 51 AML rPBSCT – ++ – +
(28–39)
24 female 39 AML RPBSCT – – – +
25 female 24 ALL uPBSCT – – – –
26 female 19 ALL uPBSCT – ++ – –
(19–29)
Abbreviations: ALL – acute lymphoblastic leukemia, AML – acute myeloid leukemia, CML – chronic myeloid leukemia, MDS –
myelodysplastic syndrome, rPBSCT – related peripheral blood stem cell transplantation, uPBSCT – unrelated peripheral blood
stem cell transplantation, uCBSCT – unrelated cord blood stem cell transplantation, rBMT – related bone marrow transplanta-
tion, uBMT – unrelated bone marrow transplantation, –: negative, +: positive in one plasma/serum sample, ++: positive in two
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Table 2. Clinical status of recipients within 180-day period after SCT
Patient no.
HHV-6 DNA  Skin rash  Pyrexia of unknown GvHD Pneumonia Time and cause
in plasma (days after  etiology  (days after (days after of death
(days after SCT) HSCT) (days after HSCT) HSCT) HSCT) (days after HSCT)
1 – 40–64 10–35 12–45 15–32 N/A
2 ++ – 10–30 – 13–30 ARDS, graft rejection
(20–30) (30)
3 – – 14–22 – – N/A
4 – – 7–14 – 10–14 ARDS, sepsis
(14)
5 – – 15–24 – – N/A
6 – – 11–30 – 15–28 ARDS
(63)
7 ++ – 15–25 – – infection, hemorrhage 
(18–25) within CNS
(25)
8 – – 16–40 18–46 18–39 N/A
9 + – 21–41 – – N/A
(63)
10 ++ 20–97 13–58 14–54 – N/A
(21–38)
11 – – 18–37; 43–87 55–74 N/A
53–78
12 – – 21–39 – – N/A
13 ++ – 12–34 – 13–34 ARDS
(18–34) (34)
14 ++ 45–72 19–35; 40–72 52–65 sepsis, multiorgan
(26–40) 39–70 failure
(140)
15 – – 10–25 – – ARDS, shock
(25)
16 – – 13–20 – – N/A
17 – – 9–37 – 15–37 N/A
18 – – 18–35 – 21–35 pneumonia
(35)
19 ++ – 9–23 – 10–23 ARDS, pneumonia
(19–23) (23)
20 – – 19–25 – – N/A
21 – – 28–32 – – N/A
22 + – 18–41 – – N/A
(58)
23 ++ – 21–32 – – N/A
(28–39)
24 – – 24–39 – – N/A
25 – – 11–17; – – N/A
28–32
26 ++ 13–29 10–29 13–29 17–29 ARDS, hemorrhage
(19–29) within CNS
(29)
Abbreviations: ARDS – acute respiratory distress syndrome, CNS – central nervous system, GvHD – graft-versus-host disease,
N/A – not applicable, –: negative, +: positive in one plasma/serum sample, ++: positive in two or more plasma samples.
tion. None of the HHV-6-positive patients had HHV-5
DNA in their plasma samples during the 180-day period.
Overall mortality in the entire group of HSCT recip-
ients during the first 180 days after transplantation was
34.6% (9 of the 26 patients) and the most frequent
direct cause of death was acute respiratory distress syn-
drome (6 patients), in some patients accompanied by
sepsis (2 patients), pneumonia (1 patient), or central
nervous system (CNS) infection (1 patients). Other
death causes included pneumonia (1 patient), bleeding
within the CNS during infectious meningitis (1 patient),
and shock during subsequent HSCT (1 patient). Seven
of the 9 patients died during the first 34 days after
HSCT (Table 2). In the HHV-6-positive patients, mor-
tality was 50% (5 out of 10 patients). Four of those
patients died during the HHV-6 viremia period, whichoccurred within the first 34 days after HSCT. Table 2
summarizes the clinical features and the times and caus-
es of death of the HSCT recipients.
DISCUSSION
Herpesviruses persist throughout life after primary
infection. Viral proliferation occurs either spontaneous-
ly or under conditions of immunosuppression.
Reactivation can lead to illnesses that typically differ in
their clinical presentation from the disease associated
with the primary infection. After SCT, reactivating
members of the β-herpesvirinae subfamily (among them
HHV-6) frequently cause serious, sometimes life-
-threatening disease [8, 12]. HHV-6 infection or reacti-
vation in these individuals has been associated with
a delay or suppression of marrow engraftment [12],
pneumonia [2], skin rash, and fever [16]. Although it is
difficult to prove an etiologic association of the virus
with these disease events, their propinquity with HHV-6
activity in the absence of other possible causes suggests
that at the very least a subset of these events is due to
HHV-6 activity.
In the present study we found that 38% (10 individ-
uals) of the graft recipients developed HHV-6 infection
(Table 1). Eight patients (30%) had detectable viral
DNA levels in two or more samples in subsequent tests
during the six weeks following SCT and another two
(8%) had a single sample positive at a later time. It is
likely that the HHV-6 infection that occurred after
transplantation was due to activation of the virus in the
bodies of the recipients, since most of the recipients
were immune to HHV-6 and no virus was found before
SCT. However, we do not know whether HHV-6 strains
detected in the present study were derived from the
donor or were transfered from other sources to the
seronegative recipients. The virus probably remains
latent in the body after primary infection, as do other
human herpesviruses. If the HHV-6 was derived from
the donor, it must have been latently infecting the
donor’s hemopoietic stem cells and was activated to
replicate after transfer to the recipient. In other cases,
the virus was probably reactivated from the recipi-
ent’s own body by factors such as a profound immune
dysfunction or an allogeneic reaction after transplan-
tation. 
We did not find any correlation between viremia and
the applied conditioning regimen or anti-GvHD pro-
phylaxis. All of the HHV-6-positive graft recipients had
fever of unknown etiology during the six weeks after
SCT and half of them (4 persons) had acute GvHD fea-
tures. Sixty-three percent of the described patients had
pneumonia and 38% skin rash. No Epstein-Barr virus or
CMV DNA was found in all the plasma samples during
HHV-6 onset (Table 1).
The exact association between HHV-6 reactivation
and mortality found in this study is not clear. Three of
the patients (38%) with detectable HHV-6 DNA levels
died during viremia shortly after transplantation, all due
to coexisting pneumonia of unconfirmed etiology.
Acyclovir in typical doses was used as an antiviral pro-
phylaxis during this period, but without any visible clin-
ical success. Studies in vitro have shown that HHV-6
DNA replication is inhibited by ganciclovir, foscarnet,
and cidofovir, but not by acyclovir [1]. 
There is a high frequency of detectable HHV-6 viral
load in SCT recipients and it may lead to an increased
risk of fatal symptomatic disease [19]. The availability of
quantitative real-time PCR means that results are avail-
able in a clinically helpful time-frame, which should
assist with implementing timely therapeutic intervention
and assessing response to treatment. Further investiga-
tion to monitor HHV-6 reactivation on a larger group of
SCT recipients will be important in improving outcome
for these patients.
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